Ordering
Available Variants5 mg
CHA.51781-5mg
Price
€200.80
Available – Dispatch in 14 days
25 mg
CHA.51781-25mg
Price
€747.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.51781-5mg | €200.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.51781-25mg | €747.20 |
≥98% (HPLC), powder, estrogen receptor modulator
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H29NO2 |
|---|---|
| CAS Number | 68047-06-3 |
| Molecular Weight | 387.51 |
| UNSPSC Code | 51111800 |
| PubChem Substance ID | 24895814 |
| NACRES | NA.77 |
| MDL number | MFCD00278780 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 300 |
| Storage condition | desiccated, protect from light |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
GHS09
   GHS08,GHS07,GHS09
|
|---|---|
| signalword | Danger |
| hcodes | H302,H350,H360FD,H410 |
| pcodes | P202 - P264 - P273 - P280 - P301 + P312 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
(Z)-4-Hydroxytamoxifen, with the CAS number 68047-06-3, is a metabolite of the anti-estrogen drug tamoxifen. It is a non-steroidal selective estrogen receptor modulator that exhibits high affinity for estrogen receptors, particularly in breast tissue. As a result, (Z)-4-Hydroxytamoxifen acts as a potent anti-estrogen, inhibiting the growth of estrogen receptor-positive breast cancer cells. Its mechanism of action involves binding to estrogen receptors, thereby blocking the action of endogenous estrogens and inducing a conformational change in the receptor that prevents the recruitment of coactivators necessary for gene transcription. This leads to a decrease in the expression of estrogen-responsive genes, ultimately resulting in the inhibition of tumor cell growth and proliferation. The compound has been extensively studied for its potential therapeutic applications in the treatment of hormone-dependent breast cancer.
